Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children 6-17 Years of Age in India: An Open-label Trial.
Agarkhedkar S, Juergens C, Balasundaram K, Agarkhedkar S, Sundaraiyer V, Le Dren-Narayanin N, Cutler MW, Gruber WC, Scott DA, Schmoele-Thoma B; B1851140 Study Team. Agarkhedkar S, et al. Pediatr Infect Dis J. 2017 Nov;36(11):e283-e285. doi: 10.1097/INF.0000000000001695. Pediatr Infect Dis J. 2017. PMID: 28719496 Clinical Trial.
Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine.
Quiambao B, Peyrani P, Li P, Cutler MW, Van Der Wielen M, Perez JL, Webber C. Quiambao B, et al. Among authors: cutler mw. Hum Vaccin Immunother. 2020 Jun 2;16(6):1272-1279. doi: 10.1080/21645515.2020.1744363. Epub 2020 May 13. Hum Vaccin Immunother. 2020. PMID: 32401600 Free PMC article. Clinical Trial.
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
Borja-Tabora CFC, Peyrani P, Webber C, Van der Wielen M, Cheuvart B, De Schrevel N, Bianco V, Aris E, Cutler M, Li P, Perez JL. Borja-Tabora CFC, et al. Among authors: cutler m. BMC Infect Dis. 2020 Jun 18;20(1):426. doi: 10.1186/s12879-020-05104-5. BMC Infect Dis. 2020. PMID: 32552685 Free PMC article. Clinical Trial.
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lörks V, Sikorski J, Hilker R, Becker D, Eller AK, Grützner J, Boesler C, Rosenbaum C, Kühnle MC, Luxemburger U, Kemmer-Brück A, Langer D, Bexon M, Bolte S, Karikó K, Palanche T, Fischer B, Schultz A, Shi PY, Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully IL, Cutler M, Kalina W, Kyratsous CA, Cooper D, Dormitzer PR, Jansen KU, Türeci Ö. Sahin U, et al. Among authors: cutler m. Nature. 2020 Oct;586(7830):594-599. doi: 10.1038/s41586-020-2814-7. Epub 2020 Sep 30. Nature. 2020. PMID: 32998157 Clinical Trial.
A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.
Cutland CL, Peyrani P, Webber C, Newton R, Cutler M, Perez JL. Cutland CL, et al. Among authors: cutler m. Vaccine. 2023 Jan 27;41(5):1153-1160. doi: 10.1016/j.vaccine.2022.11.048. Epub 2023 Jan 6. Vaccine. 2023. PMID: 36621408 Free article. Clinical Trial.
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.
Gayed J, Diya O, Lowry FS, Xu X, Bangad V, Mensa F, Zou J, Xie X, Hu Y, Lu C, Cutler M, Belanger T, Cooper D, Koury K, Anderson AS, Türeci Ö, Şahin U, Swanson KA, Modjarrad K, Gurtman A, Kitchin N; C4591054 Study Group. Gayed J, et al. Among authors: cutler m. Vaccines (Basel). 2024 Jan 24;12(2):118. doi: 10.3390/vaccines12020118. Vaccines (Basel). 2024. PMID: 38400102 Free PMC article.
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lörks V, Sikorski J, Hilker R, Becker D, Eller AK, Grützner J, Boesler C, Rosenbaum C, Kühnle MC, Luxemburger U, Kemmer-Brück A, Langer D, Bexon M, Bolte S, Karikó K, Palanche T, Fischer B, Schultz A, Shi PY, Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully IL, Cutler M, Kalina W, Kyratsous CA, Cooper D, Dormitzer PR, Jansen KU, Türeci Ö. Sahin U, et al. Among authors: cutler m. Nature. 2021 Feb;590(7844):E17. doi: 10.1038/s41586-020-03102-w. Nature. 2021. PMID: 33469214 No abstract available.
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, Quandt J, Bidmon N, Ulges A, Baum A, Pascal KE, Maurus D, Brachtendorf S, Lörks V, Sikorski J, Koch P, Hilker R, Becker D, Eller AK, Grützner J, Tonigold M, Boesler C, Rosenbaum C, Heesen L, Kühnle MC, Poran A, Dong JZ, Luxemburger U, Kemmer-Brück A, Langer D, Bexon M, Bolte S, Palanche T, Schultz A, Baumann S, Mahiny AJ, Boros G, Reinholz J, Szabó GT, Karikó K, Shi PY, Fontes-Garfias C, Perez JL, Cutler M, Cooper D, Kyratsous CA, Dormitzer PR, Jansen KU, Türeci Ö. Sahin U, et al. Among authors: cutler m. Nature. 2021 Jul;595(7868):572-577. doi: 10.1038/s41586-021-03653-6. Epub 2021 May 27. Nature. 2021. PMID: 34044428 Clinical Trial.
291 results